Trial Profile
The "ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK)" Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Losartan
- Indications Hypertension; Left ventricular hypertrophy
- Focus Biomarker; Therapeutic Use
- Acronyms ALLMARK
- Sponsors Novartis; Novartis Pharmaceuticals
- 27 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 25 Feb 2013 Planned end date changed from 1 Jun 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.